Oral sulfonylureas for the treatment of type II diabetes: an update

South Med J. 1986 Mar;79(3):337-43. doi: 10.1097/00007611-198603000-00019.

Abstract

Oral hypoglycemic agents have been in clinical use since 1956 in the United States. Two new second-generation sulfonylureas, glipizide and glyburide, have been marketed recently. This article reviews the pharmacology of the oral sulfonylureas, compares the drugs from a safety and efficacy standpoint, and provides updated information regarding their use in the management of type II non-insulin-dependent diabetes mellitus.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Administration, Oral
  • Chlorpropamide / adverse effects
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Hypersensitivity / etiology
  • Glipizide / administration & dosage
  • Glipizide / metabolism
  • Glipizide / therapeutic use
  • Glyburide / administration & dosage
  • Glyburide / metabolism
  • Glyburide / therapeutic use
  • Humans
  • Insulin Resistance
  • Kinetics
  • Liver / metabolism
  • Nausea / chemically induced
  • Patient Education as Topic
  • Sulfonylurea Compounds / administration & dosage
  • Sulfonylurea Compounds / metabolism
  • Sulfonylurea Compounds / therapeutic use*

Substances

  • Sulfonylurea Compounds
  • Glyburide
  • Chlorpropamide
  • Glipizide